Detection of other inborn errors of metabolism in hyperphenylalaninemic babies picked up on narrow-spectrum screening

Ozlem Unal1, Burcu Oztürk-Hişmi, Turgay Coşkun

  • 1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey. unalozlem@gmail.com

Insights

Limited newborn screening programs can still detect inborn errors of metabolism (IEMs). Early detection of IEMs is possible through careful physical exams and cost-effective screening techniques, even in resource-limited settings.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Background:

  • Neonatal screening programs are often limited in scope in many countries.
  • Early detection of inborn errors of metabolism (IEMs) is crucial for preventing severe health outcomes.

Purpose of the Study:

  • To highlight the opportunity for early detection of IEMs in settings with limited newborn screening.
  • To identify IEMs beyond hyperphenylalaninemia in referred neonates.

Main Methods:

  • Physical examination of neonates referred for hyperphenylalaninemia.
  • Blood sample analysis using high-performance liquid chromatography (HPLC) for phenylalanine.
  • Amino acid analysis to measure blood amino acid concentrations.

Main Results:

  • Seven patients initially referred for hyperphenylalaninemia were diagnosed with other IEMs.
  • Demonstrated the feasibility of identifying diverse IEMs through targeted investigations.

Conclusions:

  • Careful physical examination and low-cost screening methods can facilitate early detection of missed IEMs.
  • Experienced referring centers can play a vital role in expanding early IEM detection.
  • This approach offers a valuable strategy for improving newborn health in resource-limited regions.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...